查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1388103

掌腱膜挛缩症市场、份额、规模、趋势、行业分析报告：按类型、按疾病类型、按最终用途、按地区、按细分市场、预测，2023-2032年

Dupuytren Disease Market Share, Size, Trends, Industry Analysis Report, By Type ; By Disease Type ; By End-use ; By Region, And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris 市场研究的最新研究，掌腱膜挛缩症的全球市场预计到 2032 年将达到 65.2 亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

掌腱膜挛缩症是一种使人衰弱的疾病，涉及手掌组织异常增厚和缩短，导致手指畸形。 预计的市场扩张表明，有效解决和治疗这种疾病的重要性正在被认识。 随着掌腱膜挛缩症的盛行率持续增加，对有效缓解症状并改善患者整体生活品质的治疗的需求不断增长。 这种市场扩张反映了对改进治疗方案的迫切需要，以应对不断增长的患者数量并改善患者的福祉。

最近，一项研究表明阿达木单抗是一种有前途且具有成本效益的治疗选择，尤其是在早期阶段。 这些研究结果表明，阿达木单抗可以有效控制疾病状态，同时物有所值。 医疗保健专业人员和患者对该疾病的认识和了解不断增加，以及医学研究和诊断的进步，正在推动掌腱膜挛缩症治疗选择市场的扩大。

检测率的提高和及时干预增加了对有效治疗的需求。 为了解决这个问题，远籐製药发起了一项 "观看教育展开" 活动，以真实患者为主角，旨在提高对该疾病的认识。 该计划的主要目的是向公众和医疗保健界宣传可用的治疗方案。 这项活动预计将提高人们对掌腱膜挛缩症的认识，从而实现更早诊断和更好的治疗。

此外，医疗技术和治疗方法的重大进步，特别是注射胶原蛋白□和微创手术技术的发展，正在推动市场发展。 Xiaflex 是一种经批准的治疗方法，它是一种可注射胶原蛋白□，在多个国家用于治疗掌腱膜挛缩症。 与传统外科手术相比，这种方法提供了一种侵入性较小的选择，从而改善了患者的治疗效果并缩短了恢復时间。 医疗技术和治疗的进步是整个市场扩张的主要动力。

掌腱膜挛缩症市场报告亮点

II 类比比最大。

开发更有效的治疗方案使治疗领域获得最大的市场份额

欧洲透过改善医疗基础设施和加强产学合作获得最大的市场份额

主要参与者包括拜耳、诺华、辉瑞、南通清华製药、Actisa 製药和远籐国际。

目录

第 1 章简介

第 2 章执行摘要

第 3 章研究方法

第 4 章全球掌腱膜挛缩症市场洞察

  • 掌腱膜挛缩症市场 - 最终用途概况
  • 掌腱膜挛缩症市场动态
    • 推动因素和机会
      • 世界各地的人口老化正在加剧
      • 研究活动更加普遍
    • 抑制因素和挑战
      • 识别和诊断有限
  • PESTEL 分析
  • 掌腱膜挛缩症市场最终用途趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第 5 章全球掌腱膜挛缩症市场，依类型

  • 主要发现
  • 简介
  • 诊断
  • 身体检查
  • X射线
  • 治疗
  • 手术
  • 放射治疗
  • 针腱膜切开术
  • 类固醇注射
  • 酵素注射液
  • 处理中
  • 职能治疗
  • 其他

第 6 章全球掌腱膜挛缩症市场，依疾病类型

  • 主要发现
  • 简介
  • I 型
  • II 型
  • III 型

第 7 章全球掌腱膜挛缩症市场，依最终用途划分

  • 主要发现
  • 简介
  • 医院
  • 诊所
  • 学术/研究机构
  • 其他

第 8 章全球掌腱膜挛缩症市场，按地区

  • 主要发现
  • 简介
    • 掌腱膜挛缩症市场评估，按地区，2019-2032 年
  • 掌腱膜挛缩症市场 - 北美
    • 北美：掌腱膜挛缩症市场，按类型，2019-2032 年
    • 北美：掌腱膜挛缩症市场，依最终用途划分，2019-2032 年
    • 北美：掌腱膜挛缩症市场，依疾病类型划分，2019-2032 年
    • 掌腱膜挛缩症市场 - 美国
    • 掌腱膜挛缩症市场 - 加拿大
  • 掌腱膜挛缩症市场 - 欧洲
    • 欧洲：掌腱膜挛缩症市场，按类型，2019-2032 年
    • 欧洲：掌腱膜挛缩症市场，依最终用途分类，2019-2032 年
    • 欧洲：掌腱膜挛缩症市场，依疾病类型划分，2019-2032 年
    • 掌腱膜挛缩症市场 - 英国
    • 掌腱膜挛缩症市场 - 法国
    • 掌腱膜挛缩症市场 - 德国
    • 掌腱膜挛缩症市场 - 义大利
    • 掌腱膜挛缩症市场 - 西班牙
    • 掌腱膜挛缩症市场 - 荷兰
    • 掌腱膜挛缩症市场 - 俄罗斯
  • 掌腱膜挛缩症市场 - 亚太地区
    • 亚太地区：掌腱膜挛缩症市场，按类型，2019-2032 年
    • 亚太地区：掌腱膜挛缩症市场，依最终用途划分，2019-2032 年
    • 亚太地区：掌腱膜挛缩症市场，依疾病类型划分，2019-2032 年
    • 掌腱膜挛缩症市场 - 中国
    • 掌腱膜挛缩症市场 - 印度
    • 掌腱膜挛缩症市场 - 马来西亚
    • 掌腱膜挛缩症市场 - 日本
    • 掌腱膜挛缩症市场 - 印度尼西亚
    • 掌腱膜挛缩症市场 - 韩国
  • 掌腱膜挛缩症市场 - 中东和非洲
    • 中东和非洲：掌腱膜挛缩症市场，按类型，2019-2032 年
    • 中东和非洲：掌腱膜挛缩症市场，依最终用途分类，2019-2032 年
    • 中东和非洲：掌腱膜挛缩症市场，依疾病类型划分，2019-2032 年
    • 掌腱膜挛缩症市场 - 沙乌地阿拉伯
    • 掌腱膜挛缩症市场 - 阿联酋
    • 掌腱膜挛缩症市场 - 以色列
    • 掌腱膜挛缩症市场 - 南非
  • 掌腱膜挛缩症市场 - 拉丁美洲
    • 拉丁美洲：掌腱膜挛缩症市场，按类型，2019-2032 年
    • 拉丁美洲：掌腱膜挛缩症市场，依最终用途划分，2019-2032 年
    • 拉丁美洲：掌腱膜挛缩症市场，依疾病类型划分，2019-2032 年
    • 掌腱膜挛缩症市场 - 墨西哥
    • 掌腱膜挛缩症市场 - 巴西
    • 掌腱膜挛缩症市场 - 阿根廷

第 9 章竞争态势

  • 扩张与收购分析
    • 扩大
    • 收购
  • 伙伴关係/协作/协议/揭露

第 10 章公司简介

  • Actiza Pharmaceutical
  • AstraZeneca
  • Bayer
  • Bristol-Meyers
  • Endo International
  • Fresenius Kabi
  • GSK
  • Hikma Pharmaceuticals
  • LEO Pharma
  • Nantong Jinghua Pharmaceutical
  • Novartis
  • Pfizer
  • Spear Pharmaceuticals
Product Code: PM3797

The global Dupuytren disease market size is expected to reach USD 6.52 billion by 2032, according to a new study by Polaris market research. The report "Dupuytren Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Diagnosis, Treatment); By Disease Type (Type I, Type II, Type III); By End-use (Hospitals, Clinics, Academic & Research Institute, Others); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Dupuytren's disease is a debilitating condition that involves the abnormal thickening & shortening of tissue in the palm, resulting in finger deformities. The projected expansion of the market indicates a growing acknowledgment of the significance of effectively addressing and treating this condition. As the prevalence of Dupuytren's disease continues to increase, there is a rising demand for treatments that can effectively alleviate symptoms and improve the overall quality of life for affected individuals. This market expansion reflects the urgent need for improved therapeutic options to cater to the growing number of patients and enhance their well-being.

Recently, a study has highlighted adalimumab as a promising and cost-effective treatment option, especially in the early stages of the disease. These research findings indicate that adalimumab effectively manages the condition while providing good value for the investment. Growing awareness & knowledge about the disease among healthcare professionals & patients, coupled with advancements in medical research and diagnostics, are driving the expansion of the market for Dupuytren's disease treatment options.

Demand for effective treatments has risen due to improved detection rates and timely intervention. To address this, Endo Pharmaceuticals has launched the "Watching Education Unfold" campaign, which showcases real patients and seeks to raise awareness about the disease. The main objective of this initiative is to educate the public & healthcare community about the treatment options available. As a result of this campaign, it is anticipated that awareness about Dupuytren's contracture will increase, leading to earlier diagnosis and better management of the condition.

Furthermore, the market has been propelled by notable progress in medical technology and therapeutic methods, particularly the development of injectable collagenase and minimally invasive surgical techniques. One such approved treatment is Xiaflex, which employs injectable collagenase for Dupuytren's contracture in several countries. This approach provides a less invasive option compared to traditional surgical procedures, resulting in enhanced patient outcomes and faster recovery periods. These advancements in medical technology and therapeutics have emerged as major driving forces behind the overall expansion of the market.

Dupuytren Disease Market Report Highlights

Type II segment held the largest share, owing to its high prevalence, and more innovative treatment options

Treatment segment garnered the largest share, due to development of better treatment options with higher efficacy

Europe held the largest share, due to better healthcare infrastructure, strong indudtry-academia collaboration

Key players include Bayer, Novartis, Pfizer, Nantong Jinghua Pharmaceutical, Actiza Pharmaceutical, Endo International

Polaris market research has segmented the Dupuytren disease market report based on disease type, type, end use, and region:

Dupuytren Disease, Disease Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Type I
  • Type II
  • Type III

Dupuytren Disease, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Diagnosis
  • Physical Examination
  • X-ray
  • Treatment
  • Surgery
  • Radiation Therapy
  • Needle Aponeurotomy
  • Steroid Shot
  • Enzyme Injection
  • Occupational Therapy
  • Others

Dupuytren Disease, End Use Outlook (Revenue - USD Billion, 2023 - 2032)

  • Hospitals
  • Clinics
  • Academic & Research Institute
  • Others

Dupuytren Disease, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Dupuytren Disease Market Insights

  • 4.1. Dupuytren Disease Market - End Use Snapshot
  • 4.2. Dupuytren Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing aging population worldwide
      • 4.2.1.2. Rising Prevalence of Research Activities
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Awareness and Diagnosis
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Dupuytren Disease Market End Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Dupuytren Disease Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Diagnosis
    • 5.3.1. Global Dupuytren Disease Market, by Diagnosis, by Region, 2019-2032 (USD Billion)
  • 5.4. Physical Examination
    • 5.4.1. Global Dupuytren Disease Market, by Physical Examination, by Region, 2019-2032 (USD Billion)
  • 5.5. X-ray
    • 5.5.1. Global Dupuytren Disease Market, by X-ray, by Region, 2019-2032 (USD Billion)
  • 5.6. Treatment
    • 5.6.1. Global Dupuytren Disease Market, by Treatment, by Region, 2019-2032 (USD Billion)
  • 5.7. Surgery
    • 5.7.1. Global Dupuytren Disease Market, by Surgery, by Region, 2019-2032 (USD Billion)
  • 5.8. Radiation Therapy
    • 5.8.1. Global Dupuytren Disease Market, by Radiation Therapy, by Region, 2019-2032 (USD Billion)
  • 5.9. Needle Aponeurotomy
    • 5.9.1. Global Dupuytren Disease Market, by Needle Aponeurotomy, by Region, 2019-2032 (USD Billion)
  • 5.10. Steroid Shot
    • 5.10.1. Global Dupuytren Disease Market, by Steroid Shot, by Region, 2019-2032 (USD Billion)
  • 5.11. Enzyme Injection
    • 5.11.1. Global Dupuytren Disease Market, by Enzyme Injection, by Region, 2019-2032 (USD Billion)
  • 5.12. Treatment
    • 5.12.1. Global Dupuytren Disease Market, by Treatment, by Region, 2019-2032 (USD Billion)
  • 5.13. Occupational Therapy
    • 5.13.1. Global Dupuytren Disease Market, by Occupational Therapy, by Region, 2019-2032 (USD Billion)
  • 5.14. Others
    • 5.14.1. Global Dupuytren Disease Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Dupuytren Disease Market, by Disease Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 6.3. Type I
    • 6.3.1. Global Dupuytren Disease Market, by Type I, by Region, 2019-2032 (USD Billion)
  • 6.4. Type II
    • 6.4.1. Global Dupuytren Disease Market, by Type II, by Region, 2019-2032 (USD Billion)
  • 6.5. Type III
    • 6.5.1. Global Dupuytren Disease Market, by Type III, by Region, 2019-2032 (USD Billion)

7. Global Dupuytren Disease Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Dupuytren Disease Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.4. Clinics
    • 7.4.1. Global Dupuytren Disease Market, by Clinics, By Region, 2019-2032 (USD Billion)
  • 7.5. Academic & Research Institute
    • 7.5.1. Global Dupuytren Disease Market, by Academic & Research Institute, By Region, 2019-2032 (USD Billion)
  • 7.6. Others
    • 7.6.1. Global Dupuytren Disease Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Dupuytren Disease Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Dupuytren Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Dupuytren Disease Market - North America
    • 8.3.1. North America: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.3.4. Dupuytren Disease Market - U.S.
      • 8.3.4.1. U.S.: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.3.5. Dupuytren Disease Market - Canada
      • 8.3.5.1. Canada: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 8.4. Dupuytren Disease Market - Europe
    • 8.4.1. Europe: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.4. Dupuytren Disease Market - UK
      • 8.4.4.1. UK: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.5. Dupuytren Disease Market - France
      • 8.4.5.1. France: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.6. Dupuytren Disease Market - Germany
      • 8.4.6.1. Germany: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.7. Dupuytren Disease Market - Italy
      • 8.4.7.1. Italy: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.8. Dupuytren Disease Market - Spain
      • 8.4.8.1. Spain: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.9. Dupuytren Disease Market - Netherlands
      • 8.4.9.1. Netherlands: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.10. Dupuytren Disease Market - Russia
      • 8.4.10.1. Russia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 8.5. Dupuytren Disease Market - Asia Pacific
    • 8.5.1. Asia Pacific: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.4. Dupuytren Disease Market - China
      • 8.5.4.1. China: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.5. Dupuytren Disease Market - India
      • 8.5.5.1. India: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.6. Dupuytren Disease Market - Malaysia
      • 8.5.6.1. Malaysia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.7. Dupuytren Disease Market - Japan
      • 8.5.7.1. Japan: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.8. Dupuytren Disease Market - Indonesia
      • 8.5.8.1. Indonesia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.9. Dupuytren Disease Market - South Korea
      • 8.5.9.1. South Korea: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 8.6. Dupuytren Disease Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.4. Dupuytren Disease Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.5. Dupuytren Disease Market - UAE
      • 8.6.5.1. UAE: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.6. Dupuytren Disease Market - Israel
      • 8.6.6.1. Israel: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.7. Dupuytren Disease Market - South Africa
      • 8.6.7.1. South Africa: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 8.7. Dupuytren Disease Market - Latin America
    • 8.7.1. Latin America: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.4. Dupuytren Disease Market - Mexico
      • 8.7.4.1. Mexico: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.5. Dupuytren Disease Market - Brazil
      • 8.7.5.1. Brazil: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.6. Dupuytren Disease Market - Argentina
      • 8.7.6.1. Argentina: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Actiza Pharmaceutical
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2.AstraZeneca
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bayer
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bristol-Meyers
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Endo International
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Fresenius Kabi
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GSK
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Hikma Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. LEO Pharma
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Nantong Jinghua Pharmaceutical
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Novartis
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Pfizer
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Spear Pharmaceuticals
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development

List of Tables

  • Table 1 Global Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 3 Global Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 4 Dupuytren Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 7 North America: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion
  • Table 14 Europe: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 UK: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 19 UK: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 20 France: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 22 France: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 China: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 43 China: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 44 India: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 46 India: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Dupuytren Disease Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Disease Type
  • Figure 7. Global Dupuytren Disease Market, by Disease Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Dupuytren Disease Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Dupuytren Disease Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 12. Dupuytren Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Dupuytren Disease Market